

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## **EXercise to Prevent frailty and Loss Of independence in insulin treated older people with DiabetEs (EXPLODE): protocol for a feasibility randomised controlled trial (RCT)**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048932
Article Type:	Protocol
Date Submitted by the Author:	13-Jan-2021
Complete List of Authors:	Stocker, Rachel; Newcastle University Shaw, James; Newcastle University Taylor, Guy S; Newcastle University Witham, Miles; Newcastle University, NIHR Newcastle Biomedical Research Centre West, Daniel J; Newcastle University, Population Health Sciences Institute
Keywords:	DIABETES & ENDOCRINOLOGY, SPORTS MEDICINE, Clinical trials < THERAPEUTICS, GERIATRIC MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **EXercise to Prevent frailty and Loss Of independence in insulin**  
5  
6  
7  
8 **treated older people with DiabetEs (EXPLODE): protocol for a**  
9  
10  
11  
12  
13 **feasibility randomised controlled trial (RCT)**  
14  
15  
16  
17  
18  
19  
20  
21

22 Rachel Stocker<sup>1</sup>†, James A Shaw<sup>2</sup>, Guy S Taylor<sup>1</sup>, Miles D Witham<sup>2</sup>, Daniel J West<sup>1</sup>†  
23  
24

25  
26 † indicates joint corresponding author  
27  
28

29  
30 <sup>1</sup>Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University  
31  
32

33  
34 <sup>2</sup>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle  
35  
36

37 University  
38  
39  
40  
41  
42  
43

44 Corresponding authors: Dr Rachel Stocker, [rachel.stocker@newcastle.ac.uk](mailto:rachel.stocker@newcastle.ac.uk) and Dr Daniel  
45  
46

47 West, [daniel.west@newcastle.ac.uk](mailto:daniel.west@newcastle.ac.uk)  
48  
49  
50  
51  
52  
53  
54

55  
56 **Abstract**  
57  
58  
59  
60

## Introduction

There are 3.9m people in the UK with diabetes. Sarcopenia, increased frailty, and loss of independence are often unappreciated complications of diabetes. Resistance exercise shows promise in reducing these complications in non-elderly diabetes patients. The aim of this feasibility randomised controlled trial is to (1) characterise the physical function, cardiovascular health, and the health and wellbeing of older adults with insulin treated diabetes and mild frailty, (2) to test the feasibility and efficacy of a four-week resistance exercise training programme in improving these parameters, (3) to test the feasibility of recruiting and randomising the target participant group to a trial of resistance training.

## Methods and analysis

Thirty adults aged  $\geq 60$  years with insulin treated diabetes mellitus (type 1 or 2), and thirty without, all with mild frailty (3-4 on the Rockwood Frailty Scale) will be recruited. Each group will be age, gender, and frailty matched. All will complete blood, cardiovascular, and physical function testing. Each group will be randomised 1:1 to a 4-week semi-supervised resistance training programme, designed to increase muscle mass and strength, or to usual care, defined as their regular

1  
2  
3  
4 physical activity, for 4 weeks. All participants will then repeat testing. Primary  
5  
6  
7 outcomes include recruitment rate, attrition rate, intervention fidelity and  
8  
9  
10 acceptability, and adherence to the training programme. A subset of participants in  
11  
12  
13 all trial arms will be interviewed before and after the training programme to  
14  
15  
16 understand experiences of resistance training, impact on health, and living with  
17  
18 diabetes (where relevant) as they have aged. Analyses will include descriptive  
19  
20  
21 statistics and qualitative thematic analysis.  
22  
23  
24  
25  
26  
27

### 28 **Ethics and dissemination**

29  
30  
31 The North East-Newcastle & North Tyneside 2 Research Ethics Committee  
32  
33  
34 (20/NE/0178) approved the study. Outputs will include feasibility data to support  
35  
36  
37 funding applications for a future definitive trial, conference and patient and public  
38  
39  
40 involvement presentations, and peer-reviewed publications.  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Trial registration**

50  
51  
52 Current Controlled Trials: ISRCTN13193281.  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- This is a novel study to examine the feasibility of carrying out a larger trial of a gym-based resistance exercise training programme with older, mildly frail adults with insulin-treated diabetes.
- This is a single-site feasibility randomised controlled trial which will be carried out in the North East of England.
- A mixed-methods approach will explore the impact of the training programme on various clinical outcomes.
- Pre- and post- intervention qualitative interviews will generate a better understanding of the barriers and facilitators to resistance-based exercise for this important patient group, where early intervention is key.

## Introduction

## Background

There are around 425 million people with diabetes worldwide, and by 2040 it is predicted that 1 in 10 people globally will have diabetes.<sup>1</sup> In the UK there are around 4 million people living with diabetes<sup>2</sup> (90% Type 2, 8% Type 1, 2% other) with a further 1 million with undiagnosed diabetes. The prevalence of diabetes increases sharply with age, with 17.4% of those aged over 65 having diabetes, compared to 2% of those aged 16 to 44 in England.<sup>3</sup> All of those with type 1 diabetes require insulin treatment, and most of those with type 2 diabetes will eventually also require insulin treatment.<sup>4 5</sup> Diabetes represents >10% of the NHS budget in direct treatment costs.<sup>6</sup> Modern advances in diabetes treatment mean that people with diabetes are living longer<sup>7</sup>, even with the presence of the micro- and macrovascular disease associated with long-term diabetes.

With an ageing population of people living with diabetes, it is important that strategies for improving both health, quality of life, and reducing treatment burden



1  
2  
3 are identified. Long-term insulin treatment for diabetes is, however, associated with  
4  
5  
6  
7 detrimental effects to health including hypoglycaemia and weight gain<sup>8</sup>, and may  
8  
9  
10 adversely affect muscle health.<sup>9</sup> Sarcopenia in particular leads to an increased risk  
11  
12  
13 of frailty, falls, physical disability, chronic metabolic disease, and mortality.<sup>10 11</sup> The  
14  
15  
16 prevalence of frailty in older people with diabetes has been reported as ~32–48%,  
17  
18  
19 which is significantly higher than that of 5–10% in older persons without diabetes.<sup>12 13</sup>  
20  
21  
22

23  
24 Recent studies have also demonstrated an increased risk of osteoporosis and  
25  
26  
27 fracture in older people with diabetes, compared to age matched non-diabetes  
28  
29  
30 controls.<sup>14 15</sup> Thus long-term diabetes and long-term insulin treatment,  
31  
32  
33 hypoglycaemia and age related physical decline, may carry an additional burden for  
34  
35  
36 those living with insulin treated diabetes in later life.  
37  
38  
39

40  
41  
42 Physical activity and exercise interventions have been shown to improve outcomes  
43  
44  
45 associated with frailty and sarcopenia (such as muscle mass, muscle force  
46  
47  
48 production, cardiorespiratory fitness).<sup>16</sup> However, these interventions are not  
49  
50  
51 straightforward in people with insulin treated diabetes due to the risk of  
52  
53  
54 hypoglycaemia.<sup>17</sup> Aerobic exercise increases insulin sensitivity, changes the  
55  
56  
57 absorption and action of the injected insulin, and increases metabolic rate  
58  
59  
60

1  
2  
3 dramatically.<sup>18 19</sup> Under these conditions, in a person without diabetes, the insulin  
4  
5  
6  
7 concentrations would drop dramatically during and after exercise, however, in those  
8  
9  
10 with diabetes this is not possible (as the insulin is injected), and thus increases the  
11  
12  
13 risk of dangerously low blood glucose occurring. Nearly two-thirds of those with type  
14  
15  
16  
17 1 diabetes do not engage in any physical activity<sup>20</sup>, commonly due to fear of  
18  
19  
20  
21 exercise-induced hypoglycaemia.<sup>21</sup>  
22

23  
24  
25 Resistance based exercise, i.e. repeated intense muscle contractions of isolated  
26  
27  
28 parts of the body against a fixed load, is associated with less fluctuation in blood  
29  
30  
31 glucose than aerobic exercise.<sup>22-24</sup> Resistance exercise is a potent stimulus for  
32  
33  
34 improving 1) muscle mass, 2) muscle strength and power, 3) bone health, and 4)  
35  
36  
37 physical function, such as stair climbing.<sup>25 26</sup> Existing studies have shown resistance  
38  
39  
40 training to be a useful exercise modality in non-elderly, non-frail type 1 and type 2  
41  
42  
43 diabetes patients.<sup>27-29</sup> It is also the modality of exercise with the most evidence for  
44  
45  
46 improving outcomes in older adults with sarcopenia or frailty,<sup>30 31</sup> and generally well  
47  
48  
49 tolerated by this group.<sup>32</sup> However, data for its use in older adults with diabetes is  
50  
51  
52 scant. As resistance training potentially carries less risk of blood glucose fluctuation  
53  
54  
55  
56  
57  
58  
59  
60 to those with diabetes, due to differing hormonal responses to aerobic exercise, it

1  
2  
3 has potential to be a preferred modality of exercise for this group, and may help  
4  
5  
6  
7 sustain long-term engagement.<sup>22-24</sup>  
8  
9

10  
11 Given the increasing ageing diabetes population, and the increased risk of  
12  
13  
14 sarcopenia and frailty in this group, it is important to provide lifestyle related  
15  
16  
17 interventions, such as resistance training, to improve the quality of life of older  
18  
19  
20 people living with diabetes.<sup>33</sup> At present there is limited information on the physical  
21  
22  
23 function of older people with diabetes compared to those without diabetes, as well  
24  
25  
26 as how acceptable or feasible a resistance training intervention would be in this  
27  
28  
29 group.  
30  
31  
32  
33  
34  
35

36 Resistance exercise training appears to be a promising intervention to improve the  
37  
38  
39 health of those living with insulin treated diabetes, particularly those who are older.  
40  
41  
42  
43 However we have a limited understanding of what form such a resistance training  
44  
45  
46 programme might take, how and to what extent it will improve health, and how that  
47  
48  
49 might differ between those with and without diabetes.  
50  
51  
52  
53  
54  
55  
56  
57

## 58 **Aims and objectives**

59  
60

1  
2  
3  
4 The purpose of this feasibility trial is to characterise the physical function,  
5  
6  
7 cardiovascular health, and the health and wellbeing of older adults with mild frailty  
8  
9  
10 and insulin treated diabetes, and to test the feasibility of conducting a trial of  
11  
12  
13 resistance training in improving these parameters. The study has two parts: 1) to  
14  
15  
16 compare the above parameters against an age, gender, and frailty matched non-  
17  
18  
19 diabetes control group, 2) to test the feasibility and acceptability and efficacy of  
20  
21  
22 regular resistance exercise as a modality to improve health outcomes in older people  
23  
24  
25 with insulin treated diabetes.  
26  
27  
28  
29  
30  
31

## 32 **Methods and analysis**

### 33 **Trial design**

34  
35  
36  
37 This is a single-centre interventional parallel group feasibility randomised controlled  
38  
39  
40 trial conducted in Newcastle-upon-Tyne, England. Thirty participants with insulin  
41  
42  
43 treated diabetes and mild frailty, and thirty without diabetes will be randomised 1:1 to  
44  
45  
46 the intervention group, which is a 4-week programme of supervised resistance  
47  
48  
49 exercise training, or to the control group; to carry on with any usual activity as  
50  
51  
52 normal. All participants will be aged  $\geq 60$ . The current version of the protocol is v2.1.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The funder (Wellcome Trust) and sponsor (Newcastle-upon-Tyne Hospitals NHS  
4  
5  
6  
7 Foundation Trust) will have no role in the study design, conduct, data analysis,  
8  
9  
10 results interpretation, or writing.  
11  
12  
13

#### 14 **Exclusion and inclusion criteria**

15  
16  
17  
18  
19 Inclusion criteria for diabetes group (n=30):  
20  
21

- 22 • Adults  $\geq 60$  years
- 23 • Type 1 diabetes OR type 2 diabetes treated with exogenous insulin
- 24 • BMI  $< 30$  in participants with type 2 diabetes
- 25 • Rockwood Clinical Frailty Score of 3 or 4
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36

37 Inclusion criteria for non-diabetes group (n=30):  
38  
39

- 40 • Adults  $\geq 60$  years
- 41 • Rockwood Clinical Frailty Score of 3 or 4
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52

53 Exclusion criteria for all groups:  
54  
55

- 56 • History of myocardial infarction, stroke, renal failure, severe hypertension, or
- 57
- 58
- 59
- 60

1  
2  
3  
4 liver disease in the last 12 months  
5  
6

- 7
- 8 • Unsuitable for the intervention due to limiting musculoskeletal problems
  - 9
  - 10 • Inability to give written informed consent
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21

## 22 **Identification, recruitment, and consent procedures**

23

24  
25 Potential participants will be identified through the following methods: by their  
26  
27  
28  
29 treating clinician who is a clinical member of the research team, in clinic at the  
30  
31  
32 Newcastle Diabetes Centre (applicable to those with diabetes only); via poster  
33  
34  
35 adverts in GP practices and other secondary care clinics; GP practice database  
36  
37  
38 searches facilitated by the North East and North Cumbria Clinical Research Network;  
39  
40  
41  
42  
43 via social media; and via the Newcastle United Foundation charity.  
44  
45  
46  
47  
48  
49

50 A participant information sheet will be sent to potential participants. Informed written  
51  
52  
53 consent will be given and eligibility confirmed by a member of the research team.  
54  
55

56  
57 Potential participants will then be screened with the Rockwood Clinical Frailty Score,  
58  
59  
60

1  
2  
3 by either their treating diabetes clinician (where applicable) or by a member of the  
4  
5  
6  
7 research team. The study will take place from December 2020 to September 2022.  
8  
9  
10  
11  
12  
13

## 14 **Study procedures**

### 17 **Initial procedures**

18  
19  
20  
21 Participants with diabetes, and participants without, will be age, gender, and frailty  
22  
23  
24  
25 matched by the research team to ensure a similar population profile between these  
26  
27  
28 two groups.  
29  
30  
31  
32  
33  
34  
35

36 All 60 participants will undergo the following blood/cardiovascular, physical tests, and  
37  
38  
39 patient reported outcome measures at the Newcastle Clinical Research Facility, at  
40  
41  
42 the start of the trial and after the four-week intervention/control period:  
43  
44  
45  
46  
47  
48  
49

#### 50 *Blood and cardiovascular :*

- 51  
52  
53 a) resting blood pressure  
54  
55  
56  
57 b) a 15 ml blood sample will be taken via venepuncture for the quantification of:  
58  
59  
60

1  
2  
3 HbA1c, blood lipid profile, inflammatory cytokines by routine hospital clinical  
4  
5  
6  
7 chemistry or Newcastle Laboratories. 5 ml will be used to assess counts of  
8  
9  
10 endothelial progenitor cells, by flow cytometry as previously described, for a  
11  
12  
13  
14 deeper investigation of vascular health in this patient group.<sup>34</sup>  
15  
16  
17  
18  
19  
20

21 *Physical function :*  
22

- 23  
24  
25 a) Body composition: height, weight, waist circumference, % body fat, and % fat  
26  
27  
28 free mass using bioelectrical impedance analysis (SECA 515 Body  
29  
30  
31 Composition Analyser).  
32  
33  
34  
35 b) Isometric strength: a torque and strain gauge will be used to assess the force  
36  
37  
38 capability of the participants' lower limbs. This test involves maximally  
39  
40  
41 extending the leg against an immovable strain gauge, this allows for the  
42  
43  
44 calculation of peak force, and time-course changes in force.  
45  
46  
47  
48  
49 c) Handgrip strength: a digital handgrip dynamometer will be used to assess the  
50  
51  
52 maximal grip strength of the participants dominant and non-dominant hands.  
53  
54  
55  
56 d) Gait speed: using digital timing gates, the participants will be required to  
57  
58  
59 complete three 4m walking tests, to assess the normal walking speed of the  
60



1  
2  
3 participants.

- 4  
5  
6  
7 e) Timed Sit to stand: participants will sit on a chair and complete 5 stand and sit  
8  
9  
10 movements without use of the arms.  
11  
12  
13  
14  
15  
16

17  
18 *Patient reported outcome measures :*  
19

20  
21 For all participants:  
22

- 23  
24  
25 a) Health related quality of life: the Short Form-36  
26  
27

28  
29 For participants with diabetes only:  
30

- 31  
32 b) Problem Areas in Diabetes (PAID) scale  
33  
34  
35  
36 c) Hypo Fear Scale (HFS)  
37  
38  
39  
40  
41  
42

43 *Clinical history:*  
44  
45

46 For all participants, information on:  
47

- 48  
49 a) Comorbid disease  
50  
51  
52  
53 b) Current medications, including changes in medications during the trial period  
54  
55  
56  
57 c) Weight loss  
58  
59  
60

1  
2  
3 d) Exhaustion

4  
5  
6  
7 e) Physical activity levels  
8  
9

10  
11  
12  
13  
14 For participants with diabetes only, information on:  
15

16  
17 a) Insulin regimen

18  
19 b) Glucose monitoring (self-report)

20  
21  
22 c) Serious hypoglycaemic episodes over the past 12 months.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 **Randomisation**

37  
38  
39 After completing the initial testing procedures, all participants will be randomised in a  
40  
41  
42  
43 1:1 ratio to either the intervention group (4-week supervised resistance training  
44  
45  
46 programme), or the control group. This will consist of 15 (of the 30) people living with  
47  
48  
49 diabetes, and 15 (of the 30) nondiabetic controls. See Figure 1.  
50  
51  
52  
53  
54  
55  
56

57 Figure 1 here  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 Randomisation will be carried out by an individual at Newcastle University who is  
8  
9  
10 independent of the study team. Randomisation will be done in a GCP-compliant  
11  
12  
13 manner using a web-based randomisation system (<http://www.randomization.com/>).  
14  
15  
16

17  
18 This will ensure that an equal number of participants from both the diabetes and non-  
19  
20 diabetes group are assigned to the intervention and control groups.  
21  
22  
23

## 24 25 26 27 28 **Intervention** 29

30  
31  
32 The intervention is a four-week, semi-structured resistance exercise training  
33  
34 programme, designed to increase muscle mass and strength. Training will be carried  
35  
36 out at participants' most convenient public gym. The programme involves 2-3 short  
37  
38 sessions, per week, for each of the four weeks. Weeks 1 and 2 will be fully  
39  
40 supervised by a member of the research team. In week 3, participants will be asked  
41  
42 to train alone in one of the sessions, and in week 4, they will train fully  
43  
44 independently. A four-week programme has been selected to assess feasibility and  
45  
46 acceptability to participants, similar to previous feasibility work carried out in our  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 team with older adults.<sup>32</sup> The programme is not designed to induce changes in any  
4  
5  
6  
7 physical or clinical outcomes.  
8  
9

### 10 11 *Resistance exercise training programme design:* 12

13  
14  
15 Following extensive explanation and demonstration of proper exercise technique.  
16

17  
18 For each exercise, resistance is increased until momentary failure occurs within 10  
19  
20 repetitions. One repetition maximum (1RM) is estimated using a prediction equation  
21  
22 based on using the variables of 'load lifted' and 'number of repetitions completed'.<sup>35</sup>  
23  
24  
25

26  
27 This method has been previously demonstrated as a valid approach for estimating  
28  
29  
30  
31  
32  
33 1RM in older adults.<sup>36</sup>  
34  
35

36  
37  
38  
39  
40 The following exercise sessions will be completed weekly for 4 weeks:  
41  
42  
43  
44  
45  
46  
47

48 **Session 1:** Leg press, leg extension, leg curl, leg adduction, calf raises, chest press,  
49  
50  
51 shoulder press, lateral pull down, lateral raises  
52

53  
54 Repetitions: 8-12 at 70% 1RM, Sets per exercise: 3, recovery between sets: 2  
55  
56  
57  
58 minutes  
59  
60

1  
2  
3  
4  
5  
6  
7 **Session 2.** Leg press, single-leg half leg press, chest press, shoulder press, seated

8  
9  
10 row

11  
12  
13  
14 Repetitions: 5-8 at 85% 1RM, Sets per exercise: 3, recovery between sets: 4

15  
16  
17 minutes or feeling recovered.

18  
19  
20  
21  
22  
23  
24  
25 **Session 3.** Leg press, leg extension, leg curl, leg adduction, chest press, shoulder

26  
27  
28 press, lateral pull down, lateral raises

29  
30  
31  
32 Repetitions: 12–15 at 60% 1RM, Sets per exercise: 3, recovery between sets: 2

33  
34  
35 minutes

### 36 37 38 39 40 41 42 **Control arm**

43  
44  
45  
46 Participants randomised to the control arm will be asked to carry on with normal daily

47  
48  
49 activities, without any changes to any exercise they might do.

### 50 51 52 53 54 55 56 57 **Blinding**

1  
2  
3  
4 Blinding will not be possible for participants as the intervention involves undertaking  
5  
6  
7 a supervised exercise resistance training programme, with the control arm  
8  
9  
10 undertaking no additional exercise other than any usual level of activity. The clinical  
11  
12  
13 team, and the research staff responsible for analysing quantitative outcomes, will be  
14  
15  
16 blinded to treatment allocation. Research staff responsible for supervising the  
17  
18  
19 resistance training, and the qualitative aspects of the study, will not be blinded.  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Qualitative process evaluation**

29  
30  
31 We will use qualitative methods to develop an in-depth understanding of participant  
32  
33  
34 perceptions and experiences on the following topics: age and frailty, physical activity,  
35  
36  
37 living with diabetes (where relevant), barriers and facilitators to participating in the  
38  
39  
40 study and resistance training more generally, and views on the resistance training  
41  
42  
43 programme (where relevant). Topic guides are provided in Supplemental Data. Prior  
44  
45  
46 to the intervention commencing, one semi-structured interview will be conducted with  
47  
48  
49 up to 20 participants. These will be split equally between the intervention group and  
50  
51  
52 control group, and between those with and without diabetes. We will then interview  
53  
54  
55 up to 10 intervention group participants after the four-week training programme, to  
56  
57  
58  
59  
60

1  
2  
3 understand their views and experiences of the programme and perceived impact on  
4  
5  
6  
7 their health and wellbeing. We will also offer participants the option of taking part in  
8  
9  
10 this interview as a one-off procedure, without taking part in the trial, should the trial  
11  
12  
13  
14 be severely impacted by the COVID-19 global pandemic. We expect each interview  
15  
16  
17 to last 45-60 minutes. Interviews will take place at a time and location most suitable  
18  
19  
20  
21 for the participants, either face to face or over the telephone.  
22  
23  
24  
25  
26  
27  
28

### 29 **Patient and Public Involvement**

30  
31  
32  
33 Involvement of the public and stakeholders in the early stages of this study  
34  
35  
36 confirmed that the potential impact of exercise on blood glucose control, especially  
37  
38  
39 hypoglycaemia, is a common concern for people living with diabetes. Study design  
40  
41  
42  
43 was enhanced by capturing the views of several patients with insulin treated  
44  
45  
46  
47 diabetes. They reflected on the relevance and importance of the study, study  
48  
49  
50  
51 documentation and approach, and potential dissemination strategies for the public.  
52  
53  
54 Two PPI members are actively involved in this trial, influencing design and conduct.  
55  
56  
57  
58 Their input will be supported according to INVOLVE guidance.  
59  
60

## Study outcomes

### Feasibility outcomes

The primary aim of this study is acceptability and feasibility of procedures for recruitment and retention, randomization, and adherence and fidelity to the resistance training programme intervention. Recruitment rates will be calculated as the rate of invited participants who are eligible, who subsequently provide informed consent. Attrition rates will be measured, defined by discontinuation of the resistance training intervention and/or loss to follow up measurement for both conditions.

Reasons for attrition will be explored qualitatively. Acceptance, adherence and fidelity to the resistance training intervention will be monitored by the research team, who will measure session attendance, participant following intervention instructions >75% of the time, and participant self-report. Pre- and post-intervention qualitative interviews will be used to assess the acceptability of the resistance training intervention, influences on diabetes self-management where applicable, and wellbeing more generally, at baseline and at 5 weeks. Information about adverse



1  
2  
3  
4 events will be collected for the intervention group.  
5  
6  
7  
8  
9

## 10 **Secondary outcomes**

### 11 *Clinical and physical outcomes*

- 12  
13  
14  
15  
16  
17  
18 1. Body composition measured using height, weight, waist circumference,  
19  
20  
21 percentage body fat, and percentage fat-free mass using bioelectrical impedance  
22  
23  
24 analysis at baseline and 5 weeks  
25  
26  
27  
28 2. Isometric strength measured using a torque and strain gauge at baseline and 5  
29  
30  
31 weeks  
32  
33  
34  
35 3. Handgrip strength measured using a digital handgrip dynamometer at baseline  
36  
37  
38 and 5 weeks  
39  
40  
41  
42  
43 4. Gait speed measured using three 4m walking tests on digital timing gates at  
44  
45  
46 baseline and 5 weeks  
47  
48  
49  
50 5. Timed sit to stand, measured using five sit-to-stand movements at baseline and 5  
51  
52  
53 weeks  
54  
55  
56  
57 6. Cardiovascular health measured using resting blood pressure, HbA1c, blood lipid  
58  
59  
60

1  
2  
3  
4 profile, and inflammatory cytokines at baseline and 5 weeks  
5  
6

7 7. Instances of hypoglycaemia, measured weekly from baseline, obtained using  
8  
9  
10 patient self-report.  
11  
12  
13  
14  
15  
16  
17

### 18 **Sample size calculation**

19  
20  
21 This is a feasibility study with no existing data to draw upon to inform a meaningful  
22  
23  
24 sample size calculation. We have selected a sample size in line with previous  
25  
26  
27  
28 guidance on feasibility studies<sup>37</sup>, and data on key outcomes collected during this trial  
29  
30  
31  
32 will inform the sample size calculation for a larger efficacy trial in future.  
33  
34  
35  
36  
37  
38  
39

### 40 **Data collection and management**

41  
42  
43 Data will be collected by DW, RS, and GT, members of the research team.  
44  
45  
46

47 Quantitative data on blood, cardiovascular, and physical function tests will be  
48  
49  
50 gathered using a tailored case report form. Qualitative data, including non-participant  
51  
52  
53  
54 observations of the training programme, will be recorded with a voice recording  
55  
56  
57 device alongside written field notes.  
58  
59  
60

## Data analysis plan

### *Quantitative analysis*

This is a feasibility study to inform a larger trial and no hypothesis testing will be conducted. Consequently, quantitative data analysis will be descriptive. Mean, SD, range, and 95% CI will be assessed on all quantitative data to assess response rates, numbers of individuals consented and randomised, retention rate, fidelity to the intervention, and participation in the training programme and qualitative interviews. The same descriptive methods will be used to report questionnaire and assessment data at baseline and five weeks. Statistical analyses will be conducted using IBM SPSS Statistics v22 software.

### *Qualitative analysis*

Qualitative data (generated by interviews) will be analysed for thematic content. This approach is both inductive (data interrogated to answer research questions but themes allowed to 'emerge' from the data) and iterative (data collection and analysis

1  
2  
3 occurring simultaneously). All interviews will be audio recorded and transcribed  
4  
5  
6  
7 verbatim. Data analysis will involve a process of organising the data, descriptive  
8  
9  
10 coding, interpretive coding, writing and theorising. Data will be managed using a  
11  
12  
13 qualitative computer software package (NVivo v11).  
14  
15  
16

17  
18 Initially we will seek to understand each participant group (intervention and control),  
19  
20  
21 then we will explore similarities and differences across each group. Throughout this  
22  
23  
24 process, the constant comparative method of analysis will be used, with an iterative  
25  
26  
27 process of data collection and analysis. This will allow identification of initial themes  
28  
29  
30 and ideas from the data to be explored in more depth in subsequent interviews, and  
31  
32  
33 allows data from different participants to be compared and contrasted, such as  
34  
35  
36 intervention vs control participants, participants with type 1 or 2 diabetes, with  
37  
38  
39 different levels of frailty and so on. Deviant cases will be actively sought throughout  
40  
41  
42 the analysis, and emerging ideas and themes modified in response.  
43  
44  
45  
46  
47  
48  
49

### 50 **Monitoring and trial management**

51  
52  
53 A data monitoring committee has not been convened given the small size and  
54  
55  
56 feasibility focus of this trial. The Trial Management Group will provide trial oversight  
57  
58  
59  
60

1  
2  
3  
4 and monitor any safety issues that arise.  
5  
6  
7

## 8 **Ethics and dissemination** 9

10  
11  
12 Ethical approval was obtained from the UK Health Research Authority (ref:  
13

14  
15 20/NE/0178, North East - Newcastle & North Tyneside 2 Research Ethics  
16

17  
18  
19 Committee). This trial is sponsored by the Newcastle-upon-Tyne Hospitals NHS  
20

21  
22  
23 Foundation Trust (ref: 9144).  
24  
25

26  
27 The report from the clinical trial will be used for publication and oral presentation at  
28

29  
30 scientific meetings. The trial investigators aim to publish the results in writing in  
31

32  
33 clinically relevant open access journals. A summary of findings will also be  
34

35  
36  
37 distributed to our Patient and Public Involvement group.  
38  
39

40  
41 The trial was registered with an International Standard Randomised Controlled Trials  
42

43  
44  
45 Number (ISRCTN13193281) on 15/07/2020.  
46  
47  
48  
49  
50  
51

## 52 **Discussion** 53

54  
55  
56  
57 The health benefits of regular physical exercise for those with, and without, insulin  
58  
59  
60

1  
2  
3  
4 treated diabetes are numerous. Many with diabetes choose not to participate in  
5  
6  
7 physical activity, often due to fear of hypoglycaemia, or limited knowledge of  
8  
9  
10 exercise types and regimens.<sup>38</sup> There is emerging evidence that resistance exercise  
11  
12  
13 can be doubly beneficial to older adults with diabetes: it is an exercise modality  
14  
15  
16 which appears to carry less risk of hypoglycaemia than other forms of exercise, and  
17  
18  
19 has the potential to limit age-related physical deterioration exacerbated by diabetes,  
20  
21  
22 such as sarcopenia. However we have a limited understanding of what form such a  
23  
24  
25 resistance training programme might take, how and to what extent it will improve  
26  
27  
28 health, how it might impact hypoglycaemia, and how outcomes might differ between  
29  
30  
31 those with and without diabetes. In the EXPLODE study we will test the acceptability  
32  
33  
34 of one resistance exercise training programme, and gather data on how the  
35  
36  
37 programme influences the health of older people with insulin treated diabetes.  
38  
39  
40  
41  
42  
43  
44  
45 Should this feasibility study generate positive data and demonstrate participant  
46  
47  
48 acceptability, we intend to carry out a pilot randomised controlled trial of the same  
49  
50  
51 resistance training intervention over a longer duration.  
52  
53  
54  
55  
56

57 In summary, EXPLODE is a single centre feasibility randomised parallel group trial  
58  
59  
60

1  
2  
3  
4 investigating whether resistance exercise training has the potential to improve the  
5  
6  
7 health of older adults living with insulin treated diabetes. It will also provide us with  
8  
9  
10 information on the acceptability of the resistance training programme and any  
11  
12  
13  
14 required design amendments to a future larger pilot.  
15  
16  
17

### 18 **Author contributions**

19  
20  
21  
22  
23 RS contributed to research design and drafted the manuscript. DW, JS, GT, and  
24  
25  
26  
27 MDW contributed to research design and revision of the manuscript. All authors  
28  
29  
30 approved the final version of the manuscript to be published. DW is responsible for  
31  
32  
33  
34 the integrity of the work as a whole.  
35  
36  
37

### 38 **Funding statement**

39  
40  
41  
42  
43 This study is being supported by the Wellcome Trust, by a Wellcome Trust Small  
44  
45  
46  
47 Grant (grant number: N/A) to DW.  
48  
49  
50

### 51 **Competing interests**

52  
53  
54  
55  
56 None declared.  
57  
58  
59  
60

## Figure legends

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.

## References


1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Research and Clinical Practice* 2017;**128**:40-50.
2. Diabetes UK. Diabetes Prevalence 2019 2019 [Available from: <https://www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019>].
3. NHS Digital. National Diabetes Audit Report 1: Care Processes and Treatment Targets, 2018-19 2019 [Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1--care-processes-and-treatment-targets-2018-19-short-report>].
4. Ringborg A, Lindgren P, Yin D, et al. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. *Diabetes & metabolism* 2010;**36**(3):198-203.
5. Home P, Riddle M, Cefalu WT, et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? *Diabetes Care* 2014;**37**(6):1499-508.
6. Stedman M, Lunt M, Davies M, et al. Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation. *BMJ Open* 2020;**10**(5):e033231.
7. Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. *New England Journal of Medicine* 2017;**376**(15):1407-18.
8. Lebovitz HE. Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes. *Diabetes Care* 2011;**34**(Supplement 2):S225-S30.
9. Monaco CMF, Gingrich MA, Hawke TJ. Considering Type 1 Diabetes as a Form of Accelerated Muscle Aging. *Exercise and Sport Sciences Reviews* 2019;**47**(2):98-107.
10. Beaudart C, Zaaria M, Pasleau F, et al. Health outcomes of sarcopenia: a systematic review and meta-analysis. *PloS one* 2017;**12**(1):e0169548.
11. Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. *European Journal of Clinical Nutrition* 2014;**68**(9):1001-07.
12. Cacciatore F, Testa G, Galizia G, et al. Clinical frailty and long-term mortality in elderly subjects with diabetes. *Acta diabetologica* 2013;**50**(2):251-60.
13. Hubbard R, Andrew M, Fallah N, et al. Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. *Diabetic Medicine* 2010;**27**(5):603-06.
14. Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes mellitus. *Journal of Bone and Mineral Research* 2007;**22**(9):1317-28.



15. Jung H-W, Kim S-W, Ahn S, et al. Prevalence and outcomes of frailty in Korean elderly population: comparisons of a multidimensional frailty index with two phenotype models. *PloS one* 2014;**9**(2).
16. Vlietstra L, Hendrickx W, Waters DL. Exercise interventions in healthy older adults with sarcopenia: A systematic review and meta-analysis. *Australasian Journal on Ageing* 2018;**37**(3):169-83.
17. Riddell MC, Zaharieva DP, Tansey M, et al. Individual glucose responses to prolonged moderate intensity aerobic exercise in adolescents with type 1 diabetes: The higher they start, the harder they fall. *Pediatric Diabetes* 2019;**20**(1):99-106.
18. Douen AG, Ramlal T, Rastogi S, et al. Exercise induces recruitment of the "insulin-responsive glucose transporter". Evidence for distinct intracellular insulin- and exercise-recruitable transporter pools in skeletal muscle. *The Journal of biological chemistry* 1990;**265**(23):13427-30.
19. Gulve EA, Cartee GD, Zierath JR, et al. Reversal of enhanced muscle glucose transport after exercise: roles of insulin and glucose. *The American journal of physiology* 1990;**259**(5 Pt 1):E685-91.
20. Bohn B, Herbst A, Pfeifer M, et al. Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients. *Diabetes Care* 2015;**38**(8):1536-43.
21. Brazeau A-S, Rabasa-Lhoret R, Strychar I, et al. Barriers to physical activity among patients with type 1 diabetes. *Diabetes care* 2008;**31**(11):2108-09.
22. Turner D, Luzio S, Gray B, et al. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes. *Diabetic Medicine* 2016;**33**(4):506-10.
23. Turner D, Luzio S, Gray B, et al. Impact of single and multiple sets of resistance exercise in type 1 diabetes. *Scandinavian journal of medicine & science in sports* 2015;**25**(1):e99-e109.
24. Yardley JE, Kenny GP, Perkins BA, et al. Resistance Versus Aerobic Exercise. Acute effects on glycemia in type 1 diabetes. *Diabetes Care* 2013;**36**(3):537-42.
25. Bethell H. Sarcopenia, frailty and exercise. *Clinical Medicine* 2017;**17**(6):591-91.
26. Phu S, Boersma D, Duque G. Exercise and sarcopenia. *Journal of Clinical Densitometry* 2015;**18**(4):488-92.
27. Durak EP, Jovanovic-Peterson L, Peterson CM. Randomized crossover study of effect of resistance training on glycemic control, muscular strength, and cholesterol in type I diabetic men. *Diabetes Care* 1990;**13**(10):1039-43.
28. Ramalho AC, de Lourdes Lima M, Nunes F, et al. The effect of resistance versus aerobic training on metabolic control in patients with type-1 diabetes mellitus. *Diabetes Res Clin Pract* 2006;**72**(3):271-6.
29. Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;**147**(6):357-69.
30. Beckwée D, Delaere A, Aelbrecht S, et al. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. *The journal of nutrition, health & aging* 2019;**23**(6):494-502.
31. Jadcak AD, Makwana N, Luscombe-Marsh N, et al. Effectiveness of exercise interventions on physical function in community-dwelling frail older people: an umbrella review of systematic reviews. *JBI database of systematic reviews and implementation reports* 2018;**16**(3):752-75.
32. Granic A, Hurst C, Dismore L, et al. Milk and resistance exercise intervention to improve muscle function in community-dwelling older adults at risk of sarcopenia (MilkMAN): protocol for a pilot study. *BMJ Open* 2019;**9**(10):e031048.
33. Sinclair A, Gallagher A. Managing frailty and associated comorbidities in older adults with diabetes: Position Statement on behalf of the Association of British Clinical Diabetologists (ABCD), 2020.

- 1  
2  
3 34. West DJ, Campbell MD, Gonzalez JT, et al. The inflammation, vascular repair and injury responses  
4 to exercise in fit males with and without Type 1 diabetes: an observational study.  
5 Cardiovascular diabetology 2015;**14**(1):1-7.  
6  
7 35. Brzycki M. Strength testing—predicting a one-rep max from reps-to-fatigue. Journal of physical  
8 education, recreation & dance 1993;**64**(1):88-90.  
9  
10 36. Knutzen KM, Brilla LR, Caine D. Validity of 1RM prediction equations for older adults. The Journal  
11 of Strength & Conditioning Research 1999;**13**(3):242-46.  
12  
13 37. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for  
14 good practice. Journal of evaluation in clinical practice 2004;**10**(2):307-12.  
15  
16 38. Hasan S, Shaw SM, Gelling LH, et al. Exercise modes and their association with hypoglycemia  
17 episodes in adults with type 1 diabetes mellitus: a systematic review. BMJ Open Diabetes  
18 Research & Care 2018;**6**(1):e000578.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



# BMJ Open

## **EXercise to Prevent frailty and Loss Of independence in insulin treated older people with DiabetEs (EXPLODE): protocol for a feasibility randomised controlled trial (RCT)**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048932.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Sep-2021
Complete List of Authors:	Stocker, Rachel; Newcastle University Shaw, James; Newcastle University Taylor, Guy S; Newcastle University Witham, Miles; Newcastle University, NIHR Newcastle Biomedical Research Centre West, Daniel J; Newcastle University, Population Health Sciences Institute
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Geriatric medicine, Qualitative research, Sports and exercise medicine
Keywords:	DIABETES & ENDOCRINOLOGY, SPORTS MEDICINE, Clinical trials < THERAPEUTICS, GERIATRIC MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 1 **EXercise to Prevent frailty and Loss Of independence in insulin**  
5  
6  
7  
8  
9 2 **treated older people with DiabetEs (EXPLODE): protocol for a**  
10  
11  
12  
13 3 **feasibility randomised controlled trial (RCT)**  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

5 Rachel Stocker<sup>1†</sup>, James A Shaw<sup>2</sup>, Guy S Taylor<sup>1</sup>, Miles D Witham<sup>2</sup>, Daniel J West<sup>1†</sup>

6 † indicates joint corresponding author

7 <sup>1</sup>Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University

8 <sup>2</sup>Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle  
9 University

10  
11 Corresponding authors: Dr Rachel Stocker, [rachel.stocker@newcastle.ac.uk](mailto:rachel.stocker@newcastle.ac.uk) and Dr Daniel  
12 West, [daniel.west@newcastle.ac.uk](mailto:daniel.west@newcastle.ac.uk)

13  
14 **Abstract**

## 1 Introduction

2  
3  
4  
5  
6  
7 2 There are 3.9m people in the UK with diabetes. Sarcopenia, increased frailty, and  
8  
9  
10 3 loss of independence are often unappreciated complications of diabetes. Resistance  
11  
12  
13  
14 4 exercise shows promise in reducing these complications in older adult diabetes  
15  
16  
17 5 patients. The aim of this feasibility randomised controlled trial is to (1) characterise  
18  
19  
20  
21 6 the physical function, cardiovascular health, and the health and wellbeing of older  
22  
23  
24 7 adults with mild frailty with/without diabetes treated with insulin, (2) to understand the  
25  
26  
27  
28 8 feasibility and acceptability of a four-week resistance exercise training programme in  
29  
30  
31 9 improving these parameters for those with diabetes, (3) to test the feasibility of  
32  
33  
34  
35 10 recruiting and randomising the diabetic participant group to a trial of resistance  
36  
37  
38  
39 11 training.

## 12 Methods and analysis

13 13 Thirty adults aged  $\geq 60$  years with insulin-treated diabetes mellitus (type 1 or 2), and  
14  
15  
16 14 thirty without, all with mild frailty (3-4 on the Rockwood Frailty Scale) will be  
17  
18  
19  
20 15 recruited. All will complete blood, cardiovascular, and physical function testing. Only  
21  
22  
23  
24 16 the diabetic group will then proceed into the trial itself. They will be randomised 1:1  
25  
26  
27  
28 17 to a 4-week semi-supervised resistance training programme, designed to increase

1  
2  
3  
4 1 muscle mass and strength, or to usual care, defined as their regular physical activity,  
5  
6  
7 2 for 4 weeks. This group will then repeat testing. Primary outcomes include  
8  
9  
10 3 recruitment rate, attrition rate, intervention fidelity and acceptability, and adherence  
11  
12  
13  
14 4 to the training programme. A subset of participants will be interviewed before and  
15  
16  
17 5 after the training programme to understand experiences of resistance training,  
18  
19  
20  
21 6 impact on health, and living with diabetes (where relevant) as they have aged.  
22  
23  
24 7 Analyses will include descriptive statistics and qualitative thematic analysis.  
25  
26  
27

## 28 8 **Ethics and dissemination**

29  
30  
31 9 The North East-Newcastle & North Tyneside 2 Research Ethics Committee  
32  
33  
34  
35 10 (20/NE/0178) approved the study. Outputs will include feasibility data to support  
36  
37  
38  
39 11 funding applications for a future definitive trial, conference and patient and public  
40  
41  
42 12 involvement presentations, and peer-reviewed publications.  
43  
44  
45  
46 13

## 49 14 **Trial registration**

50  
51  
52  
53 15 Current Controlled Trials: ISRCTN13193281.  
54  
55  
56  
57 16  
58  
59  
60



1  
2  
3  
4 1  
5  
6  
78 2 **Strengths and limitations of this study**  
9

- 10  
11  
12 3 • This is a novel study using mixed-methods to examine the feasibility of  
13  
14  
15 4 carrying out a larger trial of a gym-based resistance exercise training  
16  
17  
18 programme with older, mildly frail adults with insulin-treated diabetes.  
19 5  
20  
21  
22 6 • A series of in-depth qualitative interviews will generate a better understanding  
23  
24  
25 of the barriers and facilitators to resistance-based exercise for this important  
26 7  
27  
28 patient group, where early intervention is key.  
29 8  
30  
31  
32 9 • This study is not intended to be a definitive trial, however, a mixed-methods  
33  
34  
35 approach will explore the impact of the training programme on various clinical  
36 10  
37  
38 outcomes and exercise experiences.  
39 11  
40  
41  
42 12 • As the study is limited to the North East of England, the sociodemographic  
43  
44  
45 characteristics of participants may differ to the population of the wider United  
46 13  
47  
48 Kingdom and other Western countries.  
49 14  
50  
51  
52  
53  
54 15  
55  
56  
57  
58  
59  
60

## 1 Introduction

## 2 Background

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

4 There are around 425 million people with diabetes worldwide, and by 2040 it is  
5 predicted that 1 in 10 people globally will have diabetes.<sup>1</sup> In the UK there are  
6 around 4 million people living with diabetes<sup>2</sup> (90% Type 2, 8% Type 1, 2% other)  
7 with a further 1 million with undiagnosed diabetes. The prevalence of diabetes  
8 increases sharply with age, with 17.4% of those aged over 65 having diabetes,  
9 compared to 2% of those aged 16 to 44 in England.<sup>3</sup> All of those with type 1 diabetes  
10 require insulin treatment, and most of those with type 2 diabetes will eventually also  
11 require insulin treatment.<sup>4 5</sup> Diabetes represents >10% of the NHS budget in direct  
12 treatment costs.<sup>6</sup> Modern advances in diabetes treatment mean that people with  
13 diabetes are living longer<sup>7</sup>, even with the presence of the micro- and macrovascular  
14 disease associated with long-term diabetes.

15 With an ageing population of people living with diabetes, it is important that  
16 strategies for improving both health, quality of life, and reducing treatment burden

1  
2  
3  
4 1 are identified. Long-term insulin treatment for diabetes is, however, associated with  
5  
6  
7 2 detrimental effects to health including hypoglycaemia and weight gain<sup>8</sup>, and may  
8  
9  
10 3 adversely affect muscle health.<sup>9</sup> Sarcopenia in particular leads to an increased risk  
11  
12  
13  
14 4 of frailty, falls, physical disability, chronic metabolic disease, and mortality.<sup>10 11</sup> The  
15  
16  
17  
18 5 prevalence of frailty in older people with diabetes has been reported as ~32–48%,  
19  
20  
21 6 which is significantly higher than that of 5–10% in older persons without diabetes.<sup>12 13</sup>  
22  
23  
24 7 Recent studies have also demonstrated an increased risk of osteoporosis and  
25  
26  
27  
28 8 fracture in older people with diabetes, compared to age matched non-diabetes  
29  
30  
31 9 controls.<sup>14 15</sup> Thus long-term diabetes and long-term insulin treatment,  
32  
33  
34  
35 10 hypoglycaemia and age related physical decline, may carry an additional burden for  
36  
37  
38  
39 11 those living with insulin treated diabetes in later life.  
40  
41  
42  
43 12 Physical activity and exercise interventions have been shown to improve outcomes  
44  
45  
46 13 associated with frailty and sarcopenia (such as muscle mass, muscle force  
47  
48  
49  
50 14 production, cardiorespiratory fitness).<sup>16</sup> However, these interventions are not  
51  
52  
53  
54 15 straightforward in people with insulin treated diabetes due to the risk of  
55  
56  
57 16 hypoglycaemia.<sup>17</sup> Aerobic exercise increases insulin sensitivity, changes the  
58  
59  
60 17 absorption and action of the injected insulin, and increases metabolic rate

1  
2  
3  
4 1 dramatically.<sup>18 19</sup> Under these conditions, in a person without diabetes, the insulin  
5  
6  
7 2 concentrations would drop dramatically during and after exercise, however, in those  
8  
9  
10 3 with diabetes this is not possible (as the insulin is injected), and thus increases the  
11  
12  
13  
14 4 risk of dangerously low blood glucose occurring. Nearly two-thirds of those with type  
15  
16  
17 5 1 diabetes do not engage in any physical activity<sup>20</sup>, commonly due to fear of  
18  
19  
20  
21 6 exercise-induced hypoglycaemia.<sup>21</sup>  
22  
23  
24  
25 7 Established insulin-treated non-obese type 2 diabetes shares many characteristics  
26  
27  
28 8 with type 1 diabetes, due to relatively greater insulin deficiency and lower insulin  
29  
30  
31  
32 9 resistance than in type 2 diabetes associated with obesity. This includes intrinsic  
33  
34  
35  
36 10 glucose variability with higher risk of impaired awareness of hypoglycaemia<sup>22 23</sup>,  
37  
38  
39 11 including severe events requiring assistance from others in treatment.<sup>24</sup> We  
40  
41  
42  
43 12 hypothesise that mild frailty may have a comparable impact in type 1 diabetes and  
44  
45  
46 13 insulin-treated type 2 diabetes where BMI is  $<30 \text{ kg/m}^2$ <sup>25</sup>, with potentially comparable  
47  
48  
49 14 impacts of resistance exercise training.  
50  
51  
52  
53 15 Resistance based exercise, i.e. repeated intense muscle contractions of isolated  
54  
55  
56  
57 16 parts of the body against a fixed load, is associated with less fluctuation in blood  
58  
59  
60

1  
2  
3  
4 1 glucose than aerobic exercise.<sup>26-28</sup> Resistance exercise is a potent stimulus for  
5  
6  
7 2 improving 1) muscle mass, 2) muscle strength and power, 3) bone health, and 4)  
8  
9  
10 3 physical function, such as stair climbing.<sup>29 30</sup> Existing studies have shown resistance  
11  
12  
13  
14 4 training to be a useful exercise modality in older, non-frail type 1 and type 2 diabetes  
15  
16  
17 5 patients.<sup>31-33</sup> It is also the modality of exercise with the most evidence for improving  
18  
19  
20  
21 6 outcomes in older people with sarcopenia or frailty,<sup>34 35</sup> and generally well tolerated  
22  
23  
24 7 by this group.<sup>36</sup> However, data for its use in older people with diabetes is scant. As  
25  
26  
27  
28 8 resistance training potentially carries less risk of blood glucose fluctuation to those  
29  
30  
31 9 with diabetes, due to differing hormonal responses to aerobic exercise, it has  
32  
33  
34  
35 10 potential to be a preferred modality of exercise for this group, and may help sustain  
36  
37  
38 11 long-term engagement.<sup>26-28</sup>

41  
42 12 Given the increasing ageing diabetes population, and the increased risk of  
43  
44  
45  
46 13 sarcopenia and frailty in this group, it is important to provide lifestyle related  
47  
48  
49  
50 14 interventions, such as resistance training, to improve the quality of life of older  
51  
52  
53 15 people living with diabetes.<sup>37</sup> At present there is limited information on the physical  
54  
55  
56  
57 16 function of older people with diabetes compared to those without diabetes, as well as  
58  
59  
60 17 how acceptable or feasible a resistance training intervention would be in this group.

1  
2  
3  
4 1 Resistance exercise training appears to be a promising intervention to improve the  
5  
6  
7 2 health of those living with insulin treated diabetes, particularly those who are older.  
8  
9  
10 3 However we have a limited understanding of what form such a resistance training  
11  
12  
13  
14 4 programme might take, and how and to what extent it will improve health.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 5 6 **Aims and objectives**

7 The purpose of this baseline case-control descriptive observational study and  
8 subsequent feasibility trial is to characterise the physical function, cardiovascular  
9 health, and the health and wellbeing of older people with mild frailty and with/without  
10 insulin-treated diabetes, and to test the feasibility of conducting a trial of resistance  
11 training in improving these parameters, and the acceptability of regular resistance  
12 exercise as a modality to improve health outcomes in older people with insulin  
13 treated diabetes.. .

## 14 **Methods and analysis**

### 15 **Study design**

16 This is a single-centre interventional feasibility randomised controlled trial with an

1  
2  
3  
4 1 associated baseline case-control descriptive observational component, and a  
5  
6  
7 2 qualitative and process evaluation component, conducted in Newcastle-upon-Tyne,  
8  
9  
10 3 England. Thirty participants with insulin treated diabetes and mild frailty, and thirty  
11  
12  
13  
14 4 without diabetes will be recruited. All participants will be aged  $\geq 60$ . All participants  
15  
16  
17 5 will undergo blood and physical testing, for the baseline case-control component.  
18  
19  
20  
21 6 The diabetic participants will then go forward into the trial. They will be randomised  
22  
23  
24 7 1:1 to the intervention group, which is a 4-week programme of supervised resistance  
25  
26  
27  
28 8 exercise training, or to the control group; to carry on with any usual activity as  
29  
30  
31 9 normal. The current version of the protocol is v3.

## 10 **Exclusion and inclusion criteria**

11 Inclusion criteria for diabetes group (n=30):

- 12 • Adults  $\geq 60$  years
- 13 • Type 1 diabetes OR type 2 diabetes treated with exogenous insulin
- 14 • BMI  $< 30$  in participants with type 2 diabetes
- 15 • Rockwood Clinical Frailty Score of 3 or 4

16 Inclusion criteria for non-diabetes group (n=30):

- 1
- 2
- 3
- 4 1 • Adults  $\geq 60$  years
- 5
- 6
- 7 2 • Rockwood Clinical Frailty Score of 3 or 4
- 8
- 9

10

11 3

12

13

14

15 4 Exclusion criteria for all groups:

16

- 17
- 18
- 19 5 • History of myocardial infarction, stroke, renal failure, severe hypertension, or
- 20
- 21
- 22
- 23 6 liver disease in the last 12 months
- 24
- 25
- 26 7 • Unsuitable for the intervention due to limiting musculoskeletal problems
- 27
- 28
- 29
- 30 8 • Inability to give written informed consent
- 31
- 32
- 33
- 34 9
- 35
- 36
- 37
- 38 10
- 39
- 40

41 **Identification, recruitment, and consent procedures**

42

43

44

45 12 All potential participants will be identified through the following methods: by their

46

47

48 13 treating clinician who is a clinical member of the research team, in clinic at the

49

50

51 14 Newcastle Diabetes Centre (applicable to those with diabetes only); via poster

52

53

54

55 15 adverts in GP practices and other secondary care clinics; GP practice database

56

57

58

59 16 searches facilitated by the North East and North Cumbria Clinical Research Network;

60



1  
2  
3  
4 1 via social media; and via the Newcastle United Foundation charity. All methods  
5  
6  
7 2 have been reviewed and approved by the Health Research Authority and the study  
8  
9  
10 3 sponsor, through their ethical and governance review processes.  
11  
12  
13  
14 4

15  
16  
17  
18 5 A participant information sheet will be sent to potential participants. Informed written  
19  
20  
21 6 consent will be given and eligibility confirmed by a member of the research team.  
22  
23  
24 7 Potential participants will then be screened with the Rockwood Clinical Frailty Score,  
25  
26  
27  
28 8 by either their treating diabetes clinician (where applicable) or by a member of the  
29  
30  
31 9 research team. The study will take place from December 2020 to September 2022.  
32  
33  
34  
35  
36 10

## 37 38 39 11 **Study procedures**

### 40 41 42 12 **Initial procedures**

43  
44  
45  
46 13 All 60 participants will undergo the following blood/cardiovascular, physical tests, and  
47  
48  
49  
50 14 patient reported outcome measures at the Newcastle Clinical Research Facility, at  
51  
52  
53 15 the start of the trial and after the four-week intervention/control period:  
54  
55  
56  
57 16

1  
2  
3  
4 1 *Blood and cardiovascular :*  
5  
6

7 2 a) resting blood pressure  
8  
9

10 3 b) a 15 ml blood sample will be taken via venepuncture for the quantification of:  
11  
12

13  
14 4 HbA1c, blood lipid profile, inflammatory cytokines by routine hospital clinical  
15

16  
17 5 chemistry or Newcastle Laboratories. 5 ml will be used to assess counts of  
18

19  
20 6 endothelial progenitor cells, by flow cytometry as previously described, for a  
21

22  
23 7 deeper investigation of vascular health in this patient group.<sup>38</sup>  
24  
25  
26  
27  
28

29 8  
30  
31

32 9 *Physical function :*  
33  
34

35 10 a) Body composition: height, weight, waist circumference, % body fat, and % fat  
36  
37

38  
39 11 free mass using bioelectrical impedance analysis (SECA 515 Body  
40

41  
42 12 Composition Analyser).  
43  
44  
45

46 13 b) Isometric strength: a torque and strain gauge will be used to assess the force  
47  
48

49  
50 14 capability of the participants' lower limbs. This test involves maximally  
51

52  
53 15 extending the leg against an immovable strain gauge, this allows for the  
54

55  
56 16 calculation of peak force, and time-course changes in force.  
57  
58

59  
60 17 c) Handgrip strength: a digital handgrip dynamometer will be used to assess the

1  
2  
3  
4 1 maximal grip strength of the participants dominant and non-dominant hands.  
5  
6

7 2 d) Gait speed: using digital timing gates, the participants will be required to  
8  
9

10 3 complete three 4m walking tests, to assess the normal walking speed of the  
11  
12

13  
14 4 participants.  
15  
16

17 5 e) Timed Sit to stand: participants will sit on a chair and complete 5 stand and sit  
18  
19

20 6 movements without use of the arms.  
21  
22  
23  
24  
25  
26  
27

28 8 *Patient reported outcome measures :*  
29  
30  
31

32 9 For all participants:  
33  
34

35 10 a) Health related quality of life: the Short Form-36  
36  
37  
38

39 11 For participants with diabetes only:  
40  
41  
42

43 12 b) Problem Areas in Diabetes (PAID) scale  
44  
45

46 13 c) Hypo Fear Scale (HFS)  
47  
48  
49

50 14  
51  
52

53 15 *Clinical history:*  
54  
55

56 16 For all participants, information on:  
57  
58  
59  
60

- 1
- 2
- 3
- 4 1 a) Comorbid disease
- 5
- 6
- 7 2 b) Current medications, including changes in medications during the trial period
- 8
- 9
- 10 3 c) Weight loss
- 11
- 12
- 13
- 14 4 d) Exhaustion
- 15
- 16
- 17 5 e) Physical activity levels (using the International Physical Activity Questionnaire,
- 18
- 19
- 20
- 21 6 short form)
- 22
- 23
- 24
- 25 7
- 26
- 27

28 8 For participants with diabetes only, information on:

- 31 9 a) Insulin regimen
- 32
- 33
- 34
- 35 10 b) Glucose monitoring (self-report)
- 36
- 37
- 38
- 39 11 c) Serious hypoglycaemic episodes over the past 12 months.
- 40
- 41
- 42
- 43 12
- 44
- 45
- 46
- 47 13
- 48
- 49

## 50 14 **Randomisation**

51

52

53 15 After completing the initial testing procedures, the diabetic group (n=30) will be

54

55

56

57 16 randomised in a 1:1 ratio to either the intervention group (4-week supervised

58

59

60

1  
2  
3  
4 1 resistance training programme), or the control group. See Figure 1.  
5  
6  
7  
8  
9

10  
11  
12  
13  
14  
15 2  
16  
17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

3 Figure 1 here

4

5 Randomisation of the diabetic group will take place at the end of the baseline visit.

6 Randomisation will be done in a GCP-compliant manner using a web-based

7 randomisation system (<http://www.randomization.com/>). The allocation sequence will

8 be prepared by individuals who will remain independent of the study team to

9 preserve allocation concealment. The randomisation code sequence will not be

10 accessible by the study team until after the trial analysis is complete.

11

## 12 **Intervention**

13 The intervention is a four-week, semi-structured resistance exercise training

14 programme, designed to increase muscle mass and strength. Training will be carried

15 out at participants' preferred public gym, and facilitated by a trained member of the

16 research team. The programme involves 2-3 sessions lasting less than one hour

1 each, per week, for each of the four weeks. Weeks 1 and 2 will be fully supervised  
2 by a member of the research team. In week 3, participants will be asked to train  
3 alone in one of the sessions, and in week 4, they will train fully independently. A four-  
4 week programme has been selected to assess feasibility and acceptability to  
5 participants, similar to previous feasibility work carried out in our team with older  
6 people.<sup>36</sup> The programme is not designed to induce changes in any physical or  
7 clinical outcomes.

8 The trial will be carried out once all relevant Covid-19 restrictions have been lifted in  
9 England. The research team will also adhere to Covid-19 standard operating  
10 protocols specified by the sponsor.

#### 12 ***Resistance exercise training programme design:***

13 Following extensive explanation and demonstration of proper exercise technique.  
14 For each exercise, resistance is increased until momentary failure occurs within 10  
15 repetitions. One repetition maximum (1RM) is estimated using a prediction equation  
16 based on using the variables of 'load lifted' and 'number of repetitions completed'.<sup>39</sup>

1  
2  
3  
4 1 This method has been previously demonstrated as a valid approach for estimating  
5  
6  
7 2 1RM in older people.<sup>40</sup>  
8  
9

10  
11 3  
12  
13  
14  
15 4 The following exercise sessions will be completed weekly for 4 weeks:  
16  
17

18  
19 5  
20  
21  
22 6 **Session 1:** Leg press, leg extension, leg curl, leg adduction, calf raises, chest press,  
23  
24  
25 7 shoulder press, lateral pull down, lateral raises  
26  
27

28  
29 8 Repetitions: 8-12 at 70% 1RM, Sets per exercise: 3, recovery between sets: 2  
30  
31  
32 9 minutes  
33  
34  
35

36 10  
37  
38  
39  
40 11 **Session 2:** Leg press, single-leg half leg press, chest press, shoulder press, seated  
41  
42  
43 12 row  
44  
45

46  
47 13 Repetitions: 5-8 at 85% 1RM, Sets per exercise: 3, recovery between sets: 4  
48  
49  
50 14 minutes or feeling recovered.  
51  
52

53  
54 15  
55  
56  
57 16 **Session 3:** Leg press, leg extension, leg curl, leg adduction, chest press, shoulder  
58  
59  
60

1  
2  
3  
4 1 press, lateral pull down, lateral raises  
5  
6

7 2 Repetitions: 12–15 at 60% 1RM, Sets per exercise: 3, recovery between sets: 2  
8  
9

10 3 minutes  
11  
12  
13  
14  
15 4  
16  
17

### 18 5 **Control arm**

19  
20  
21 6 Participants randomised to the control arm will be asked to carry on with normal daily  
22  
23  
24  
25 7 activities, without any changes to any exercise they might do.  
26  
27  
28  
29 8

### 30 31 32 9 **Blinding**

33  
34  
35  
36 10 Blinding will not be possible for participants as the intervention involves undertaking  
37  
38  
39 11 a supervised exercise resistance training programme, with the control arm  
40  
41  
42  
43 12 undertaking no additional exercise other than any usual level of activity. The clinical  
44  
45  
46 13 team, and the research staff responsible for analysing quantitative outcomes, will be  
47  
48  
49  
50 14 blinded to treatment allocation. Research staff responsible for supervising the  
51  
52  
53 15 resistance training, and the qualitative aspects of the study, will not be blinded.  
54  
55  
56  
57 16



## 1 Qualitative process evaluation

2 We will use qualitative methods to develop an in-depth understanding of participant  
3 perceptions and experiences on the following topics: age and frailty, physical activity,  
4 living with diabetes (where relevant), barriers and facilitators to participating in the  
5 study and resistance training more generally, and views on the resistance training  
6 programme (where relevant). Topic guides are provided in Supplemental Data. Prior  
7 to the intervention commencing, one semi-structured interview will be conducted with  
8 up to 20 participants. These will be split equally between the intervention group and  
9 control group, and between those with and without diabetes. We will then interview  
10 up to 10 intervention group participants after the four-week training programme, to  
11 understand their views and experiences of the programme and perceived impact on  
12 their health and wellbeing. We will also offer participants the option of taking part in  
13 this interview as a one-off procedure, without taking part in the trial, should the trial  
14 be severely impacted by the COVID-19 global pandemic. We expect each interview  
15 to last 45-60 minutes. Interviews will take place at a time and location most suitable  
16 for the participants, either face to face or over the telephone. All participants will be  
17 approached for interview in order of recruitment. We anticipate that the sample sizes

1  
2  
3  
4 1 described will allow data saturation, and interviews will cease once no new semantic  
5  
6  
7 2 codes are identified from our concurrent thematic analysis of these data (code  
8  
9  
10 3 saturation).<sup>41</sup>  
11  
12  
13  
14  
15 4  
16  
17  
18

## 19 5 **Patient and Public Involvement**

20  
21  
22  
23 6 Involvement of the public and stakeholders in the early stages of this study  
24  
25  
26 7 confirmed that the potential impact of exercise on blood glucose control, especially  
27  
28  
29  
30 8 hypoglycaemia, is a common concern for people living with diabetes. Study design  
31  
32  
33 9 was enhanced by capturing the views of several patients with insulin treated  
34  
35  
36  
37 10 diabetes. They reflected on the relevance and importance of the study, study  
38  
39  
40 11 documentation and approach, and potential dissemination strategies for the public.  
41  
42  
43  
44 12 Two PPI members are actively involved in this trial, influencing design and conduct.  
45  
46  
47 13 Their input will be supported according to INVOLVE guidance.  
48  
49  
50  
51  
52 14  
53  
54  
55

## 56 15 **Study outcomes**

### 59 16 **Feasibility outcomes**

1  
2  
3  
4 1 The primary aim of this study is acceptability and feasibility of procedures for  
5  
6  
7 2 recruitment and retention, randomization, and adherence and fidelity to the  
8  
9  
10 3 resistance training programme intervention. We will use a traffic light approach,  
11  
12  
13  
14 4 where green = proceed without modification; amber = proceed but with modification,  
15  
16  
17 5 red = unrealistic to proceed without major modification. Recruitment rates will be  
18  
19  
20  
21 6 calculated as the rate of invited participants who are eligible, who subsequently  
22  
23  
24 7 provide informed consent. Green = >50% recruitment, amber = 25-50% recruitment,  
25  
26  
27  
28 8 red = <25% recruitment. Attrition rates will be measured, defined by discontinuation  
29  
30  
31 9 of the resistance training intervention and/or loss to follow up measurement for both  
32  
33  
34  
35 10 conditions. Green = <10% attrition, amber = 10-20% attrition, red = >20% attrition.  
36  
37  
38 11 Reasons for attrition will be explored qualitatively. Acceptance, adherence and  
39  
40  
41  
42 12 fidelity to the resistance training intervention will be monitored by the research team,  
43  
44  
45 13 who will measure session attendance: green = >90% attendance, amber = 75-90%  
46  
47  
48  
49 14 attendance, red = <75% attendance, plus participant following intervention  
50  
51  
52 15 instructions >75% of the time, and participant self-report. Pre- and post-intervention  
53  
54  
55  
56 16 qualitative interviews will be used to assess the acceptability of the resistance  
57  
58  
59 17 training intervention, influences on diabetes self-management where applicable, and  
60

1  
2  
3  
4 1 wellbeing more generally, at baseline and at 5 weeks. Information about adverse  
5  
6  
7 2 events will be collected for the intervention group.  
8  
9

10  
11 3  
12

#### 14 4 **Secondary outcomes**

##### 18 5 *Clinical and physical outcomes*

- 21 6 1. Body composition measured using height, weight, waist circumference,  
23  
24  
25 7 percentage body fat, and percentage fat-free mass using bioelectrical impedance  
26  
27  
28 8 analysis at baseline and 5 weeks  
29  
30  
31  
32 9 2. Isometric strength measured using a torque and strain gauge at baseline and 5  
33  
34  
35 10 weeks  
36  
37  
38  
39 11 3. Handgrip strength measured using a digital handgrip dynamometer at baseline  
40  
41  
42 12 and 5 weeks  
43  
44  
45  
46 13 4. Gait speed measured using three 4m walking tests on digital timing gates at  
47  
48  
49 14 baseline and 5 weeks  
50  
51  
52  
53 15 5. Timed sit to stand, measured using five sit-to-stand movements at baseline and 5  
54  
55  
56 16 weeks  
57  
58  
59  
60

1  
2  
3  
4 1 6. Cardiovascular health measured using resting blood pressure, HbA1c, blood lipid  
5  
6  
7 2 profile, and inflammatory cytokines at baseline and 5 weeks  
8  
9

10  
11 3 7. Instances of hypoglycaemia, measured weekly from baseline, obtained using  
12  
13  
14 4 patient self-report.  
15  
16

## 17 5 18 19 20 21 6 **Sample size calculation**

22  
23  
24  
25 7 This is a feasibility study with no existing data to draw upon to inform a meaningful  
26  
27  
28 8 sample size calculation. We have selected a sample size in line with previous  
29  
30  
31  
32 9 guidance on feasibility studies<sup>42</sup>, and data on key outcomes collected during this trial  
33  
34  
35 10 will inform the sample size calculation for a larger efficacy trial in future.  
36  
37  
38  
39  
40 11

## 41 42 43 12 **Data collection and management**

44  
45  
46  
47 13 Data will be collected by DW, RS, and GT, members of the research team.  
48  
49  
50  
51 14 Quantitative data on blood, cardiovascular, and physical function tests will be  
52  
53  
54 15 gathered using a tailored case report form. Qualitative data, including non-participant  
55  
56  
57  
58 16 observations of the training programme, will be recorded with a voice recording  
59  
60

1  
2  
3  
4 1 device alongside written field notes.  
5  
6

7 2  
8  
9

### 10 3 **Data analysis plan**

#### 11 4 *Quantitative analysis*

12  
13  
14  
15  
16  
17  
18 5 This is a feasibility study to inform a larger trial and no hypothesis testing will be  
19  
20  
21  
22 6 conducted. Consequently, quantitative data analysis will be descriptive. Mean, SD,  
23  
24  
25 7 range, and 95% CI will be assessed on all quantitative data to assess response  
26  
27  
28 8 rates, numbers of individuals consented and randomised, retention rate, fidelity to  
29  
30  
31  
32 9 the intervention, and participation in the training programme and qualitative  
33  
34  
35  
36 10 interviews. The same descriptive methods will be used to report questionnaire and  
37  
38  
39 11 assessment data at baseline and five weeks. Statistical analyses will be conducted  
40  
41  
42  
43 12 using IBM SPSS Statistics v22 software.  
44  
45

46 13  
47  
48

#### 49 14 *Qualitative analysis*

50  
51  
52  
53 15 Qualitative data (generated by interviews) will be analysed for thematic content. This  
54  
55  
56  
57 16 approach is both inductive (data interrogated to answer research questions but  
58  
59  
60

1  
2  
3  
4 1 themes allowed to 'emerge' from the data) and iterative (data collection and analysis  
5  
6  
7 2 occurring simultaneously). All interviews will be audio recorded and transcribed  
8  
9  
10 3 verbatim. Data analysis will involve a process of organising the data, descriptive  
11  
12  
13  
14 4 coding, interpretive coding, writing and theorising. Data will be managed using a  
15  
16  
17 5 qualitative computer software package (NVivo v11).  
18  
19  
20

21 6 Initially we will seek to understand each participant group (intervention and control),  
22  
23  
24  
25 7 then we will explore similarities and differences across each group. Throughout this  
26  
27  
28 8 process, the constant comparative method of analysis will be used, with an iterative  
29  
30  
31  
32 9 process of data collection and analysis. This will allow identification of initial themes  
33  
34  
35  
36 10 and ideas from the data to be explored in more depth in subsequent interviews, and  
37  
38  
39 11 allows data from different participants to be compared and contrasted, such as  
40  
41  
42 12 intervention vs control participants, participants with type 1 or 2 diabetes, with  
43  
44  
45  
46 13 different levels of frailty and so on. Deviant cases will be actively sought throughout  
47  
48  
49 14 the analysis, and emerging ideas and themes modified in response.  
50  
51  
52

## 53 15 **Monitoring and trial management**

54  
55  
56  
57 16 A data monitoring committee has not been convened given the small size and  
58  
59  
60

1  
2  
3  
4 1 feasibility focus of this trial. The Trial Management Group will provide trial oversight  
5  
6  
7 2 and monitor any safety issues that arise.  
8  
9

### 10 11 12 3 **Ethics and dissemination**

13  
14  
15 4 Ethical approval was obtained from the UK Health Research Authority (ref:  
16  
17  
18  
19 5 20/NE/0178, North East - Newcastle & North Tyneside 2 Research Ethics  
20  
21  
22 6 Committee). This trial is sponsored by the Newcastle-upon-Tyne Hospitals NHS  
23  
24  
25  
26 7 Foundation Trust (ref: 9144).  
27  
28

29  
30 8 The report from the clinical trial will be used for publication and oral presentation at  
31  
32  
33 9 scientific meetings. The trial investigators aim to publish the results in writing in  
34  
35  
36  
37 10 clinically relevant open access journals. A summary of findings will also be  
38  
39  
40  
41 11 distributed to our Patient and Public Involvement group.  
42  
43  
44

45 12 The trial was registered with an International Standard Randomised Controlled Trials  
46  
47  
48 13 Number (ISRCTN13193281) on 15/07/2020.  
49  
50

### 51 52 53 54 55 56 15 **Discussion** 57 58 59 60



1  
2  
3  
4 1 The health benefits of regular physical exercise for those with, and without, insulin  
5  
6  
7 2 treated diabetes are numerous. Many with diabetes choose not to participate in  
8  
9  
10 3 physical activity, often due to fear of hypoglycaemia, or limited knowledge of  
11  
12  
13  
14 4 exercise types and regimens.<sup>43</sup> There is emerging evidence that resistance exercise  
15  
16  
17 5 can be doubly beneficial to older people with diabetes: it is an exercise modality  
18  
19  
20  
21 6 which appears to carry less risk of hypoglycaemia than other forms of exercise, and  
22  
23  
24  
25 7 has the potential to limit age-related physical deterioration exacerbated by diabetes,  
26  
27  
28 8 such as sarcopenia. However we have a limited understanding of what form such a  
29  
30  
31 9 resistance training programme might take, how and to what extent it will improve  
32  
33  
34  
35 10 health, how it might impact hypoglycaemia, and how outcomes might differ between  
36  
37  
38  
39 11 those with and without diabetes. In the EXPLODE study we will test the acceptability  
40  
41  
42 12 of one resistance exercise training programme, and gather data on how the  
43  
44  
45  
46 13 programme influences the health of older people with insulin treated diabetes.  
47  
48  
49 14 Should this feasibility study generate positive data and demonstrate participant  
50  
51  
52 15 acceptability, we intend to carry out a pilot randomised controlled trial of the same  
53  
54  
55  
56 16 resistance training intervention over a longer duration.  
57  
58  
59  
60

1  
2  
3  
4 1 In summary, EXPLODE is a single centre feasibility randomised parallel group trial  
5  
6  
7 2 investigating whether resistance exercise training has the potential to improve the  
8  
9  
10 3 health of older people living with insulin treated diabetes. It will also provide us with  
11  
12  
13  
14 4 information on the acceptability of the resistance training programme and any  
15  
16  
17 5 required design amendments to a future larger pilot.  
18  
19  
20  
21

## 22 6 **Author contributions**

23  
24  
25  
26  
27 7 RS contributed to research design and drafted the manuscript. DW, JS, GT, and  
28  
29  
30 8 MDW contributed to research design and revision of the manuscript. All authors  
31  
32  
33  
34 9 approved the final version of the manuscript to be published. DW is responsible for  
35  
36  
37 10 the integrity of the work as a whole.  
38  
39  
40  
41

## 42 11 **Funding statement**

43  
44  
45  
46  
47 12 This study is being supported by the Wellcome Trust, by a Wellcome Trust Small  
48  
49  
50 13 Grant (grant number: N/A) to DW.  
51  
52  
53  
54  
55 14 The funder (Wellcome Trust) and sponsor (Newcastle-upon-Tyne Hospitals NHS  
56  
57  
58 15 Foundation Trust) will have no role in the study design, conduct, data analysis,  
59  
60

1  
2  
3  
4 1 results interpretation, or writing.  
5  
6  
7

8 **2 Competing interests**  
9

10  
11  
12  
13 3 None declared.  
14  
15  
16

17 **4 Figure legends**  
18  
19  
20  
21  
22

23 5 Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.  
24  
25  
26  
27  
28  
29  
30  
31

32 **7 References**  
33  
34

35 8 1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global  
36

37  
38 9 estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes*  
39

40  
41  
42 10 *Research and Clinical Practice* 2017;128:40-50. doi:  
43

44  
45 11 10.1016/j.diabres.2017.03.024  
46  
47  
48

49 12 2. Diabetes UK. Diabetes Prevalence 2019 2019 [Available from:  
50

51  
52 13 [54  
55  
56 14 \[reports/statistics/diabetes-prevalence-2019\]\(https://www.diabetes.org.uk/professionals/position-statements-<br/>57</a><br/>58<br/>59<br/>60<br/><a href=\) accessed 28/09/2020.](https://www.diabetes.org.uk/professionals/position-statements-<br/>53</a></p></div><div data-bbox=)

- 1  
2  
3  
4 1 3. NHS Digital. National Diabetes Audit Report 1: Care Processes and Treatment  
5  
6  
7 2 Targets, 2018-19 2019 [Available from: [https://digital.nhs.uk/data-and-](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1--care-processes-and-treatment-targets-2018-19-short-report)  
8  
9  
10 3 [information/publications/statistical/national-diabetes-audit/report-1--care-](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1--care-processes-and-treatment-targets-2018-19-short-report)  
11  
12  
13  
14 4 [processes-and-treatment-targets-2018-19-short-report](https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1--care-processes-and-treatment-targets-2018-19-short-report) accessed 28/09/2020.  
15  
16  
17 5 4. Ringborg A, Lindgren P, Yin D, et al. Time to insulin treatment and factors  
18  
19  
20  
21 6 associated with insulin prescription in Swedish patients with type 2 diabetes.  
22  
23  
24 7 *Diabetes & metabolism* 2010;36(3):198-203.  
25  
26  
27  
28 8 5. Home P, Riddle M, Cefalu WT, et al. Insulin Therapy in People With Type 2  
29  
30  
31 9 Diabetes: Opportunities and Challenges? *Diabetes Care* 2014;37(6):1499-  
32  
33  
34  
35 10 508. doi: 10.2337/dc13-2743  
36  
37  
38 11 6. Stedman M, Lunt M, Davies M, et al. Cost of hospital treatment of type 1 diabetes  
39  
40  
41  
42 12 (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes  
43  
44  
45 13 population: a detailed economic evaluation. *BMJ Open* 2020;10(5):e033231.  
46  
47  
48  
49 14 doi: 10.1136/bmjopen-2019-033231  
50  
51  
52 15 7. Rawshani A, Rawshani A, Franzén S, et al. Mortality and Cardiovascular Disease  
53  
54  
55  
56 16 in Type 1 and Type 2 Diabetes. *New England Journal of Medicine*  
57  
58  
59 17 2017;376(15):1407-18. doi: 10.1056/NEJMoa1608664  
60

- 1  
2  
3  
4 1 8. Lebovitz HE. Insulin: Potential Negative Consequences of Early Routine Use in  
5  
6  
7 2 Patients With Type 2 Diabetes. *Diabetes Care* 2011;34(Supplement 2):S225-  
8  
9  
10 3 S30. doi: 10.2337/dc11-s225  
11  
12  
13  
14 4 9. Monaco CMF, Gingrich MA, Hawke TJ. Considering Type 1 Diabetes as a Form of  
15  
16  
17 5 Accelerated Muscle Aging. *Exercise and Sport Sciences Reviews*  
18  
19  
20 6 2019;47(2):98-107. doi: 10.1249/jes.000000000000184  
21  
22  
23  
24 7 10. Beaudart C, Zaaria M, Pasleau F, et al. Health outcomes of sarcopenia: a  
25  
26  
27 8 systematic review and meta-analysis. *PloS one* 2017;12(1):e0169548.  
28  
29  
30  
31 9 11. Batsis JA, Mackenzie TA, Barre LK, et al. Sarcopenia, sarcopenic obesity and  
32  
33  
34 10 mortality in older adults: results from the National Health and Nutrition  
35  
36  
37 11 Examination Survey III. *European Journal of Clinical Nutrition*  
38  
39  
40  
41 12 2014;68(9):1001-07. doi: 10.1038/ejcn.2014.117  
42  
43  
44  
45 13 12. Cacciatore F, Testa G, Galizia G, et al. Clinical frailty and long-term mortality in  
46  
47  
48 14 elderly subjects with diabetes. *Acta diabetologica* 2013;50(2):251-60.  
49  
50  
51  
52 15 13. Hubbard R, Andrew M, Fallah N, et al. Comparison of the prognostic importance  
53  
54  
55 16 of diagnosed diabetes, co-morbidity and frailty in older people. *Diabetic*  
56  
57  
58 17 *Medicine* 2010;27(5):603-06.  
59  
60

- 1  
2  
3  
4 1 14. Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes  
5  
6  
7 2 mellitus. *Journal of Bone and Mineral Research* 2007;22(9):1317-28.  
8  
9  
10  
11 3 15. Jung H-W, Kim S-W, Ahn S, et al. Prevalence and outcomes of frailty in Korean  
12  
13  
14 4 elderly population: comparisons of a multidimensional frailty index with two  
15  
16  
17 5 phenotype models. *PloS one* 2014;9(2)  
18  
19  
20  
21 6 16. Vlietstra L, Hendrickx W, Waters DL. Exercise interventions in healthy older  
22  
23  
24 7 adults with sarcopenia: A systematic review and meta-analysis. *Australasian*  
25  
26  
27 8 *Journal on Ageing* 2018;37(3):169-83. doi: 10.1111/ajag.12521  
28  
29  
30  
31 9 17. Riddell MC, Zaharieva DP, Tansey M, et al. Individual glucose responses to  
32  
33  
34 10 prolonged moderate intensity aerobic exercise in adolescents with type 1  
35  
36  
37 11 diabetes: The higher they start, the harder they fall. *Pediatric Diabetes*  
38  
39  
40  
41 12 2019;20(1):99-106. doi: 10.1111/pedi.12799  
42  
43  
44  
45 13 18. Douen AG, Ramlal T, Rastogi S, et al. Exercise induces recruitment of the  
46  
47  
48 14 "insulin-responsive glucose transporter". Evidence for distinct intracellular  
49  
50  
51  
52 15 insulin- and exercise-recruitable transporter pools in skeletal muscle. *The*  
53  
54  
55 16 *Journal of biological chemistry* 1990;265(23):13427-30. [published Online  
56  
57  
58  
59 17 First: 1990/08/15]  
60

- 1  
2  
3  
4 1 19. Gulve EA, Cartee GD, Zierath JR, et al. Reversal of enhanced muscle glucose  
5  
6  
7 2 transport after exercise: roles of insulin and glucose. *The American journal of*  
8  
9  
10 3 *physiology* 1990;259(5 Pt 1):E685-91. doi: 10.1152/ajpendo.1990.259.5.E685  
11  
12  
13  
14 4 [published Online First: 1990/11/01]  
15  
16  
17 5 20. Bohn B, Herbst A, Pfeifer M, et al. Impact of Physical Activity on Glycemic  
18  
19  
20  
21 6 Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1  
22  
23  
24 7 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients. *Diabetes*  
25  
26  
27 8 *Care* 2015;38(8):1536-43. doi: 10.2337/dc15-0030  
28  
29  
30  
31 9 21. Brazeau A-S, Rabasa-Lhoret R, Strychar I, et al. Barriers to physical activity  
32  
33  
34 10 among patients with type 1 diabetes. *Diabetes care* 2008;31(11):2108-09.  
35  
36  
37  
38 11 22. Yun JS, Park YM, Han K, et al. Association between BMI and risk of severe  
39  
40  
41 12 hypoglycaemia in type 2 diabetes. *Diabetes Metab* 2019;45(1):19-25. doi:  
42  
43  
44 13 10.1016/j.diabet.2018.03.006 [published Online First: 2018/04/06]  
45  
46  
47  
48 14 23. van Meijel LA, de Vegt F, Abbink EJ, et al. High prevalence of impaired  
49  
50  
51 15 awareness of hypoglycemia and severe hypoglycemia among people with  
52  
53  
54 16 insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort. *BMJ Open*  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 *Diabetes Research & Care* 2020;8(1):e000935. doi: 10.1136/bmjdr-  
5  
6  
7 2 2019-000935  
8  
9  
10 3 24. Horii T, Oikawa Y, Kunisada N, et al. Real-world risk of hypoglycemia-related  
11  
12  
13  
14 4 hospitalization in Japanese patients with type 2 diabetes using SGLT2  
15  
16  
17 5 inhibitors: a nationwide cohort study. *BMJ Open Diabetes Research and Care*  
18  
19  
20  
21 6 2020;8(2):e001856.  
22  
23  
24 7 25. Izzo A, Massimino E, Riccardi G, et al. A Narrative Review on Sarcopenia in  
25  
26  
27  
28 8 Type 2 Diabetes Mellitus: Prevalence and Associated Factors. *Nutrients*  
29  
30  
31 9 2021;13(1) doi: 10.3390/nu13010183 [published Online First: 2021/01/14]  
32  
33  
34  
35 10 26. Turner D, Luzio S, Gray B, et al. Algorithm that delivers an individualized  
36  
37  
38 11 rapid-acting insulin dose after morning resistance exercise counters  
39  
40  
41  
42 12 post-exercise hyperglycaemia in people with Type 1 diabetes. *Diabetic*  
43  
44  
45 13 *Medicine* 2016;33(4):506-10.  
46  
47  
48  
49 14 27. Turner D, Luzio S, Gray B, et al. Impact of single and multiple sets of resistance  
50  
51  
52 15 exercise in type 1 diabetes. *Scandinavian journal of medicine & science in*  
53  
54  
55  
56 16 *sports* 2015;25(1):e99-e109.  
57  
58  
59  
60



- 1  
2  
3  
4 1 28. Yardley JE, Kenny GP, Perkins BA, et al. Resistance Versus Aerobic Exercise.  
5  
6  
7 2 *Acute effects on glycemia in type 1 diabetes* 2013;36(3):537-42. doi:  
8  
9  
10 3 10.2337/dc12-0963  
11  
12  
13  
14 4 29. Bethell H. Sarcopenia, frailty and exercise. *Clinical Medicine* 2017;17(6):591-91.  
15  
16  
17 5 30. Phu S, Boersma D, Duque G. Exercise and sarcopenia. *Journal of Clinical*  
18  
19  
20 6 *Densitometry* 2015;18(4):488-92.  
21  
22  
23  
24 7 31. Durak EP, Jovanovic-Peterson L, Peterson CM. Randomized crossover study of  
25  
26  
27 8 effect of resistance training on glycemic control, muscular strength, and  
28  
29  
30 9 cholesterol in type I diabetic men. *Diabetes Care* 1990;13(10):1039-43. doi:  
31  
32  
33 10 10.2337/diacare.13.10.1039 [published Online First: 1990/10/01]  
34  
35  
36  
37  
38 11 32. Ramalho AC, de Lourdes Lima M, Nunes F, et al. The effect of resistance versus  
39  
40  
41 12 aerobic training on metabolic control in patients with type-1 diabetes mellitus.  
42  
43  
44 13 *Diabetes Res Clin Pract* 2006;72(3):271-6. doi: 10.1016/j.diabres.2005.11.011  
45  
46  
47 14 [published Online First: 2006/01/13]  
48  
49  
50  
51  
52 15 33. Sigal RJ, Kenny GP, Boulé NG, et al. Effects of aerobic training, resistance  
53  
54  
55 16 training, or both on glycemic control in type 2 diabetes: a randomized trial.  
56  
57  
58  
59  
60


- 1  
2  
3  
4 1 *Ann Intern Med* 2007;147(6):357-69. doi: 10.7326/0003-4819-147-6-  
5  
6  
7 2 200709180-00005 [published Online First: 2007/09/19]  
8  
9  
10 3 34. Beckwée D, Delaere A, Aelbrecht S, et al. Exercise Interventions for the  
11  
12  
13  
14 4 Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. *The*  
15  
16  
17 5 *journal of nutrition, health & aging* 2019;23(6):494-502. doi: 10.1007/s12603-  
18  
19  
20  
21 6 019-1196-8 [published Online First: 2019/06/25]  
22  
23  
24 7 35. Jadczyk AD, Makwana N, Luscombe-Marsh N, et al. Effectiveness of exercise  
25  
26  
27  
28 8 interventions on physical function in community-dwelling frail older people: an  
29  
30  
31 9 umbrella review of systematic reviews. *JBI database of systematic reviews*  
32  
33  
34  
35 10 *and implementation reports* 2018;16(3):752-75. doi: 10.11124/jbisrir-2017-  
36  
37  
38 11 003551 [published Online First: 2018/03/10]  
39  
40  
41  
42 12 36. Granic A, Hurst C, Dismore L, et al. Milk and resistance exercise intervention to  
43  
44  
45 13 improve muscle function in community-dwelling older adults at risk of  
46  
47  
48  
49 14 sarcopenia (MilkMAN): protocol for a pilot study. *BMJ Open*  
50  
51  
52 15 2019;9(10):e031048. doi: 10.1136/bmjopen-2019-031048  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 1 37. Sinclair A, Gallagher A. Managing frailty and associated comorbidities in older  
5  
6  
7 2 adults with diabetes: Position Statement on behalf of the Association of British  
8  
9  
10 3 Clinical Diabetologists (ABCD), 2020.  
11  
12  
13  
14 4 38. West DJ, Campbell MD, Gonzalez JT, et al. The inflammation, vascular repair  
15  
16  
17 5 and injury responses to exercise in fit males with and without Type 1 diabetes:  
18  
19  
20 6 an observational study. *Cardiovascular diabetology* 2015;14(1):1-7.  
21  
22  
23  
24 7 39. Brzycki M. Strength testing—predicting a one-rep max from reps-to-fatigue.  
25  
26  
27 8 *Journal of physical education, recreation & dance* 1993;64(1):88-90.  
28  
29  
30  
31 9 40. Knutzen KM, Brilla LR, Caine D. Validity of 1RM prediction equations for older  
32  
33  
34 10 adults. *The Journal of Strength & Conditioning Research* 1999;13(3):242-46.  
35  
36  
37  
38 11 41. Braun V, Clarke V. Reflecting on reflexive thematic analysis. *Qualitative*  
39  
40  
41 12 *Research in Sport, Exercise and Health* 2019;11(4):589-97.  
42  
43  
44  
45 13 42. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies:  
46  
47  
48 14 recommendations for good practice. *Journal of evaluation in clinical practice*  
49  
50  
51  
52 15 2004;10(2):307-12. doi: 10.1111/j..2002.384.doc.x [published Online First:  
53  
54  
55  
56 16 2004/06/11]

- 1  
2  
3  
4 1 43. Hasan S, Shaw SM, Gelling LH, et al. Exercise modes and their association with  
5  
6  
7 2 hypoglycemia episodes in adults with type 1 diabetes mellitus: a systematic  
8  
9  
10 3 review. *BMJ Open Diabetes Research & Care* 2018;6(1):e000578. doi:  
11  
12  
13  
14 4 10.1136/bmjdr-2018-000578  
15  
16  
17  
18 5  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a pilot or feasibility randomised trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	1-2
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	4-6
	2b	Specific objectives or research questions for pilot trial	6-7
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	7
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	n/a – protocol paper
Participants	4a	Eligibility criteria for participants	7-8
	4b	Settings and locations where the data were collected	8-9
	4c	How participants were identified and consented	
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	9-11
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	15-16
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	n/a – protocol paper
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	15-16
Sample size	7a	Rationale for numbers in the pilot trial	17
	7b	When applicable, explanation of any interim analyses and stopping guidelines	n/a – protocol paper
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	11
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	11

Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	11
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	11
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	13
	11b	If relevant, description of the similarity of interventions	n/a – protocol paper
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	14, 17-18
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	n/a – protocol paper
	13b	For each group, losses and exclusions after randomisation, together with reasons	n/a – protocol paper
Recruitment	14a	Dates defining the periods of recruitment and follow-up	n/a – protocol paper
	14b	Why the pilot trial ended or was stopped	n/a – protocol paper
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	n/a – protocol paper
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	n/a – protocol paper
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	n/a – protocol paper
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	n/a – protocol paper
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	n/a – protocol paper
	19a	If relevant, other important unintended consequences	n/a – protocol paper
<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	

Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	19
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	n/a – protocol paper
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	n/a – protocol paper
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	2
Protocol	24	Where the pilot trial protocol can be accessed, if available	n/a
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	20
	26	Ethical approval or approval by research review committee, confirmed with reference number	2

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).